EGRX Eagle Pharmaceuticals, Inc. Stock Quote

EGRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	49.90	EPS (ttm)	0.89	Insider Own	12.30%	Shs Outstand	13.06M	Perf Week	7.55%
Market Cap	580.46M	Forward P/E	11.03	EPS next Y	4.02	Insider Trans	0.00%	Shs Float	10.12M	Perf Month	-1.03%
Income	12.00M	PEG	18.48	EPS next Q	0.74	Inst Own	95.30%	Short Float	13.86%	Perf Quarter	-10.58%
Sales	187.80M	P/S	3.09	EPS this Y	-14.00%	Inst Trans	-3.13%	Short Ratio	11.25	Perf Half Y	-3.08%
Book/sh	14.24	P/B	3.11	EPS next Y	22.58%	ROA	4.30%	Target Price	48.00	Perf Year	-7.76%
Cash/sh	7.88	P/C	5.62	EPS next 5Y	2.70%	ROE	6.60%	52W Range	36.48 - 56.16	Perf YTD	-4.85%
Dividend	-	P/FCF	11.89	EPS past 5Y	40.60%	ROI	10.20%	52W High	-20.83%	Beta	0.79
Dividend %	-	Quick Ratio	4.10	Sales past 5Y	23.20%	Gross Margin	75.80%	52W Low	21.87%	ATR	1.51
Employees	106	Current Ratio	4.40	Sales Q/Q	3.30%	Oper. Margin	17.50%	RSI (14)	57.98	Volatility	3.09% 3.73%
Optionable	Yes	Debt/Eq	0.18	EPS Q/Q	748.50%	Profit Margin	6.40%	Rel Volume	0.50	Prev Close	44.31
Shortable	Yes	LT Debt/Eq	0.13	Earnings	Mar 02 BMO	Payout	0.00%	Avg Volume	124.68K	Price	44.46
Recom	2.20	SMA20	5.07%	SMA50	0.25%	SMA200	-2.18%	Volume	34,260	Change	0.34%

Apr-07-21

Resumed

RBC Capital Mkts

Outperform

$52

Nov-01-18

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Oct-31-18

Downgrade

Piper Jaffray

Overweight → Neutral

Mar-21-18

Reiterated

Mizuho

Underperform

$37 → $40

Nov-09-17

Reiterated

RBC Capital Mkts

Outperform

$81 → $75

Sep-06-17

Reiterated

Mizuho

Underperform

$40 → $37

Jul-27-17

Reiterated

RBC Capital Mkts

Outperform

$94 → $81

Jul-27-17

Reiterated

Mizuho

Underperform

$57 → $40

May-09-17

Reiterated

RBC Capital Mkts

Outperform

$86 → $94

Jan-09-17

Downgrade

Mizuho

Neutral → Underperform

$78 → $64

Nov-16-16

Downgrade

Mizuho

Buy → Neutral

$78

Nov-03-16

Upgrade

Mizuho

Neutral → Buy

$62 → $78

Nov-03-16

Reiterated

RBC Capital Mkts

Outperform

$80 → $93

Oct-26-16

Reiterated

Mizuho

Buy

$65 → $62

Aug-16-16

Reiterated

Mizuho

Neutral

$47 → $65

Jun-20-16

Downgrade

Mizuho

Buy → Neutral

$66 → $47

May-10-16

Reiterated

RBC Capital Mkts

Outperform

$94 → $78

Mar-18-16

Reiterated

Mizuho

Buy

$81 → $71

Feb-26-16

Reiterated

Mizuho

Buy

$112 → $81

Dec-09-15

Initiated

Mizuho

Buy

$112

Apr-15-21 03:22AM	We Think Eagle Pharmaceuticals (NASDAQ:EGRX) Can Manage Its Debt With Ease Simply Wall St.
Mar-15-21 04:08PM	Top Pharmaceutical Stocks for Q2 2021 Investopedia
Mar-03-21 12:23AM	Is Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Trading At A 21% Discount? Simply Wall St.
Mar-02-21 02:00PM	Eagle Pharmaceuticals Inc (EGRX) Q4 2020 Earnings Call Transcript Motley Fool -10.97%
08:15AM	Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates Zacks
06:50AM	Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review Business Wire
06:30AM	Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-01-21 10:15AM	Earnings Preview: Eagle Pharmaceuticals Benzinga
Feb-22-21 04:30PM	Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021 Business Wire
Feb-02-21 07:45AM	FDA Rejects Eagle Pharma's Vasopressin Application Benzinga
06:50AM	Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial Business Wire
Feb-01-21 06:50AM	Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed Business Wire
Jan-11-21 06:50AM	Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns Business Wire
Jan-04-21 04:30PM	Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-03-21 02:45AM	Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? Simply Wall St.
Dec-15-20 07:27PM	Is EGRX A Good Stock To Buy Now? Insider Monkey
Nov-23-20 06:50AM	Eagle Pharmaceuticals Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing Business Wire
Nov-04-20 06:10AM	Eagle Pharmaceuticals, Inc. Just Beat EPS By 2,450%: Here's What Analysts Think Will Happen Next Simply Wall St.
Nov-02-20 12:30PM	Eagle Pharmaceuticals Inc (EGRX) Q3 2020 Earnings Call Transcript Motley Fool +5.80%
08:24AM	Eagle Pharmaceuticals: Q3 Earnings Insights Benzinga
08:05AM	Eagle Pharmaceuticals (EGRX) Beats Q3 Earnings and Revenue Estimates Zacks
06:47AM	Eagle Pharmaceuticals Reports Third Quarter 2020 Results Business Wire
06:45AM	Eagle Pharmaceuticals Strengthens Management Team to Prepare for Future Growth Business Wire
Oct-26-20 04:30PM	Eagle Pharmaceuticals to Discuss Third Quarter 2020 Financial Results on November 2, 2020 Business Wire
Oct-15-20 09:20AM	New Strong Sell Stocks for October 15th Zacks
08:19AM	Reflecting on Eagle Pharmaceuticals' (NASDAQ:EGRX) Share Price Returns Over The Last Year Simply Wall St.
Sep-25-20 02:13PM	Eagle Pharmaceuticals (EGRX) Has Fallen 26% in Last One Year, Underperforms Market Insider Monkey
Sep-24-20 11:30AM	Companies Are Starting to Buy Back Stock Again. Why Thats Good News. CoinDesk
11:30AM	Companies Are Starting to Buy Back Stock Again. Why Thats Good News. Barrons.com
06:50AM	Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program Business Wire
Sep-23-20 06:50AM	Eagle Pharmaceuticals Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute ("RTD") Formulation, with Launch Expected in January 2021 Business Wire
Sep-09-20 11:07AM	Eagle Pharmaceuticals (EGRX) Has Fallen 38% in Last One Year, Underperforms Market Insider Monkey
Sep-08-20 06:50AM	Eagle Pharmaceuticals to Present at Upcoming September 2020 Healthcare Conferences Business Wire
Aug-19-20 06:50AM	Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimers Disease Business Wire
Aug-10-20 01:30PM	Eagle Pharmaceuticals Inc (EGRX) Q2 2020 Earnings Call Transcript Motley Fool -7.96%
08:15AM	Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates Zacks
07:06AM	Recap: Eagle Pharmaceuticals Q2 Earnings Benzinga
06:50AM	Eagle Pharmaceuticals Reports Second Quarter 2020 Results Business Wire
Aug-03-20 04:30PM	Eagle Pharmaceuticals to Discuss Second Quarter 2020 Financial Results on August 10, 2020 Business Wire
Jul-31-20 03:56PM	Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Benzinga
Jul-17-20 11:47AM	Is Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? Simply Wall St.
Jul-09-20 12:00PM	CMS Establishes Unique J-Code for Eagle Pharmaceuticals PEMFEXY (Pemetrexed for Injection) Business Wire
Jun-27-20 09:28PM	Hedge Funds Are Buying Eagle Pharmaceuticals Inc (EGRX) Insider Monkey
Jun-10-20 04:08PM	Edited Transcript of EGRX earnings conference call or presentation 11-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-26-20 04:30PM	Eagle Pharmaceuticals to Present at June Investor Conferences Business Wire
May-22-20 04:05PM	Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders Business Wire
May-14-20 11:50AM	Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Just Slashed This Year's Estimates Simply Wall St.
May-12-20 04:30PM	Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference Business Wire
May-11-20 12:30PM	Eagle Pharmaceuticals Inc (EGRX) Q1 2020 Earnings Call Transcript Motley Fool
08:35AM	Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates Zacks
08:14AM	Eagle Pharmaceuticals: Q1 Earnings Insights Benzinga
07:22AM	A Look At The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Simply Wall St.
06:50AM	Eagle Pharmaceuticals Reports First Quarter 2020 Results Business Wire
May-08-20 08:41AM	Why Eagle Pharmaceuticals (EGRX) Might Surprise This Earnings Season Zacks
May-07-20 06:07AM	3 Medical Product Stocks Set to Beat This Earnings Season Zacks
May-04-20 06:50AM	Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration ("FDA") Business Wire
Apr-29-20 04:30PM	Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020 Business Wire
Apr-28-20 12:33PM	Earnings Preview: Eagle Pharmaceuticals (EGRX) Q1 Earnings Expected to Decline Zacks
06:50AM	Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection) Business Wire
Apr-16-20 05:24PM	Covid Report: Gilead Pops On Promising Sneak Peek For Coronavirus Drug Investor's Business Daily +7.14%
06:50AM	Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2 Business Wire
Apr-11-20 09:25AM	What Is Eagle Pharmaceuticals's (NASDAQ:EGRX) P/E Ratio After Its Share Price Rocketed? Simply Wall St.
Mar-30-20 06:50AM	Eagle Pharmaceuticals Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation Business Wire +12.91%
Mar-24-20 02:20AM	Edited Transcript of EGRX earnings conference call or presentation 2-Mar-20 1:30pm GMT Thomson Reuters StreetEvents +5.87%
Mar-10-20 07:55AM	What Is Eagle Pharmaceuticals's (NASDAQ:EGRX) P/E Ratio After Its Share Price Tanked? Simply Wall St. +5.69%
Mar-02-20 08:15AM	Eagle Pharmaceuticals (EGRX) Surpasses Q4 Earnings and Revenue Estimates Zacks -8.80%
06:50AM	Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results Business Wire
Feb-24-20 12:30PM	Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline Zacks
Feb-19-20 04:30PM	Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 Business Wire
Feb-13-20 07:50AM	Eagle Pharmaceuticals (NASDAQ:EGRX) Has A Pretty Healthy Balance Sheet Simply Wall St.
Feb-10-20 09:54AM	Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY (Pemetrexed for Injection) Business Wire
Jan-13-20 06:50AM	Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimers Disease in Collaboration With University of Pennsylvania Business Wire
Jan-09-20 08:40AM	Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study Zacks
06:50AM	Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke Business Wire
Jan-08-20 10:18AM	Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks
08:16AM	Is Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) ROE Of 15% Concerning? Simply Wall St.
Jan-07-20 09:25AM	Tyme stock rises on Eage collaboration for cancer drug MarketWatch
07:20AM	Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer Business Wire
Jan-06-20 06:50AM	Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury Business Wire
Dec-23-19 06:50AM	Eagle Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-19 06:50AM	Eagle Pharmaceuticals Granted Orphan Drug Designation for RYANODEX (dantrolene sodium) for Treatment of Organophosphate Exposure (Nerve Agents) Business Wire
Dec-13-19 02:53PM	Eagle Pharmaceuticals Reaches Settlement Agreement with Eli Lilly for PEMFEXY (pemetrexed for injection) Business Wire
Dec-11-19 11:25AM	Eagle Pharmaceuticals Inc (EGRX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-09-19 06:50AM	Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate Business Wire
Dec-03-19 08:45AM	If You Had Bought Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Five Years Ago, You Could Pocket A 336% Gain Today Simply Wall St.
Nov-21-19 07:49AM	Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 06:50AM	Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-19 06:50AM	Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors Business Wire
Nov-12-19 08:15AM	Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates Zacks -5.61%
06:51AM	Eagle Pharmaceuticals Reports Third Quarter 2019 Results Business Wire
06:50AM	Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage Business Wire
Nov-09-19 02:26PM	Do Hedge Funds Love Eagle Pharmaceuticals Inc (EGRX)? Insider Monkey
Nov-05-19 10:31AM	Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-31-19 04:30PM	Eagle Pharmaceuticals to Discuss Third Quarter 2019 Financial Results on November 12, 2019 Business Wire
10:34AM	Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-19 08:02AM	An Intrinsic Calculation For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Suggests It's 39% Undervalued Simply Wall St.
Oct-17-19 09:28AM	New Strong Sell Stocks for October 17th Zacks
Oct-07-19 06:50AM	Eagle Pharmaceuticals Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation Business Wire
Oct-02-19 02:39PM	Here's What Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) P/E Is Telling Us Simply Wall St.
Sep-24-19 11:30AM	Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez Zacks

Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RATOFF STEVEN B	Director	Apr 08	Option Exercise	7.33	7,020	51,433	27,364	Apr 12 04:38 PM
Tarriff Scott	CEO	Apr 01	Option Exercise	8.78	31,201	273,945	1,561,184	Apr 05 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience